Drugs / human allogenic HPyV-2-specific T cells
human allogenic HPyV-2-specific T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06990087 | Feb 2026 → Nov 2027 expected | progressive multifocal leukoencephalopathy | Hannover Medical School | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | human allogenic HPyV-2-specific T cells | “For this reason, the investigational medicinal product (IMP) called 'human allogenic HPyV-2-specific T cells' is to be tested in this study.” NCT06990087 ↗ |
| Modality | Cell therapy | “The investigational medicinal products (IMPs) under test are fresh and cryopreserved allogeneic HPyV-2-specific T-lymphocyte apheresis concentrates.” NCT06990087 ↗ |
| Route | Intravenous | “Route of administration: Intravenous” NCT06990087 ↗ |